查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015237

早洩治療市場：2026-2032年全球市場預測（依治療方法、劑型、給藥途徑、起效類型、性別、最終用戶及通路分類）

Premature Ejaculation Treatment Market by Treatment Type, Dosage Form, Route of Administration, Onset Type, Treatment Accessibility, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，早洩治療市場價值將達到 35.2 億美元，到 2026 年將成長至 38 億美元，到 2032 年將達到 60.5 億美元，複合年成長率為 8.04%。

主要市場統計數據
基準年 2025 35.2億美元
預計年份：2026年 38億美元
預測年份 2032 60.5億美元
複合年成長率 (%) 8.04%

早洩治療現況策略概述：臨床挑戰、病患進展、不斷發展的照護模式和未滿足的需求概述

早洩的治療涉及臨床科學、病患行為和商業性創新三者之間的複雜交會。患者的症狀表現和合併症各不相同，因此需要進行個別化的評估和治療方案。臨床醫生在選擇各種干預措施時，會考慮療效、耐受性、起效時間、易用性和患者偏好，這些干預措施包括行為療法、醫療設備以及全身性和局部藥物治療。此外，不斷變化的監管預期、患者權益倡導以及對生活品質（QOL）日益成長的關注，都進一步影響著這種治療格局。

治療方法的變革、數位療法的普及、監管政策的轉變以及商業性趨勢正在重新定義臨床護理和產業的重點。

近年來，早洩的概念、診斷和治療發生了顯著變化。數位療法和行為療法的進步擴大了實證介入措施的覆蓋範圍，使患者能夠獲得以往僅限於面對面諮詢的治療。同時，醫療設備設計的創新，例如靶向收縮環和先進的振動刺激平台，拓寬了非藥物治療的選擇，並促進了以患者為中心的自我管理策略。此外，外用製劑的改進也為這些變化提供了補充，這些製劑經過最佳化，起效迅速且耐受性良好。

評估 2025 年美國關稅環境及其對治療方法和醫療設備相關人員的營運、供應鏈和商業影響。

美國將於2025年加徵關稅，為早洩治療藥物和醫療設備的生產、進口和分銷環節的相關人員帶來了新的經濟變數。依賴跨境採購活性成分、醫療設備組件或成品的供應鏈如今面臨更嚴格的審查，促使企業重新評估籌資策略。製造商和供應商正在透過評估替代貨源、實現生產地域多角化以及談判更加注重關稅風險和總到岸成本的供應合約來應對這一挑戰。

將治療方法、終端用戶管道和劑型聯繫起來的詳細細分分析，為產品開發和商業化策略提供了見解。

細分市場分析揭示了產品開發、商業化和臨床應用路徑的細微差異，這些差異主要受不同治療方法、終端使用者和劑型的影響。根據治療方法，治療方法包括非藥物療法、全身性藥物療法和局部療法。非藥物療法又可細分為行為療法和醫療設備，其中行為療法又可細分為感覺集中訓練和啟動-停止訓練等技術，而醫療設備則涵蓋了諸如束縛環製劑和振動刺激等療法。全身性藥物療法包括磷酸二酯酶抑制劑和選擇性血清素再回收抑制劑（SSRIs）等藥物。前者包括Sildenafil和他達拉非等藥物，後者包括達泊西汀等專用藥物，以及Fluoxetine、帕羅西汀和舍曲林等仿單標示外用藥的SSRIs。局部治療的特點是使用局部麻醉劑，常見的製劑包括Lidocaine乳膏、Lidocaine-Prilocaine噴霧劑和Prilocaine乳膏。

美洲、歐洲、中東、非洲和亞太地區成功實施所需的關鍵區域趨勢和差異化策略方法。

區域趨勢正在以不同的方式影響美洲、歐洲、中東、非洲和亞太地區的監管路徑、支付方行為和臨床實踐。在美洲，法律規範和支付方參與專注於療效比較和報銷合理性，而醫療服務模式則傾向於結合診所和居家照護護理，並納入遠距遠端醫療和私人保險公司。在歐洲、中東和非洲，由於管理體制和醫療保健體系的多樣性，需要製定針對特定區域的證據方案，並與當地相關人員開展合作，其中真實世界療效和成本效益評估在某些市場尤為重要。在亞太地區，數位技術的快速普及、多樣化的報銷環境以及對本地化臨床檢驗的高度重視，意味著打入市場策略依賴於夥伴關係、本地監管專業知識和適應當地文化的病人參與計畫。

企業層面的策略趨勢，重點在於產品差異化、夥伴關係模式以及在整體競爭格局中產生證據的優先事項。

在藥理學、醫療設備和行為療法領域，競爭日益呈現融合趨勢，各公司競相研發差異化的製劑、給藥機制和服務導向護理模式。後期研發公司和成熟製造商正投資於速效外用製劑和結合藥理作用與行為支持的策略，而醫療設備創新者則專注於易用性、隱蔽性以及持續療效的證據。製藥研發公司與數位醫療服務提供者之間的策略合作也正在興起，旨在透過將治療藥物與用藥依從性支持和行為指導相結合，從而改善治療效果。

為領導者提供實用建議，以整合臨床差異化、供應鏈韌性和以患者為中心的商業化，從而取得長期成功。

產業領導者應採取多管齊下的策略，整合臨床差異化、供應鏈韌性和以病人為中心的商業化。首先，優先考慮那些能夠展現快速起效、良好耐受性和有意義的患者報告結局（PRO）的臨床項目，可以提升新療法的臨床可信度。其次，實施多元化的籌資策略，探索近岸外包和雙源採購安排，可以在保持成本競爭力的同時，降低關稅和供應鏈風險。

採用穩健的混合調查方法，結合關鍵相關人員的訪談、第二手資料的整合以及供應鏈情境分析。

本執行摘要的研究採用了一種混合方法，結合了質性訪談、二手文獻整合、監管文件審查和供應鏈分析。主要研究包括對臨床醫生、臨床試驗研究人員、支付方和商業領域領導者進行結構化訪談，以收集有關治療方法選擇、報銷障礙和患者依從性模式的第一手資料。二手資訊涵蓋了同儕審查的臨床文獻、監管指導文件、臨床試驗註冊資訊和專利，以檢驗治療機制、安全性訊號和證據方面的不足。

簡明扼要的結論整合了臨床、營運和商業性要求，旨在促進早洩治療中的護理並改善治療效果。

總而言之，早洩治療領域正經歷著顯著的變革，其特點是外用藥物的進步、醫療設備的創新、數位化行為支持的運用以及監管和商業性趨勢的轉變。這些趨勢凸顯了整合式方法的重要性，該方法需要將可靠的臨床證據與以患者為中心的服務模式和穩健的營運結構相結合。積極應對關稅造成的供應鏈相關人員、根據診所、居家照護和醫院等不同終端用戶的偏好客製化產品設計、並向支付方展現清晰價值的利益相關者，將更有利於推動臨床應用並維持良好的商業性績效。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：早洩治療市場（依治療方法分類）

  • 非藥物療法
    • 行為療法
      • 感官濃度
      • 啟停法
    • 醫療設備
      • 緊固環
      • 震動刺激
  • 藥物治療
    • 磷酸二酯酶抑制劑
      • Sildenafil
      • 他達拉非
    • 選擇性血清素再回收抑制劑
      • 達泊西汀
      • Fluoxetine
    • 局部麻醉劑
    • 密碼鎖

第9章 早洩治療藥物市場（依劑型分類）

  • 奶油
  • 噴
  • 藥片

第10章：早洩治療市場：依給藥途徑分類

  • 口服
  • 外用

第11章：早洩治療市場（依發病類型分類）

  • 自然早洩
  • 後天性早洩

第12章 早洩治療市場：治療可近性與性別

  • 處方箋藥
  • 非處方藥

第13章：早洩治療市場：依最終用戶分類

  • 診所
  • 居家照護
  • 醫院

第14章 早洩治療市場：依通路分類

  • 線上
  • 離線

第15章：早洩治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 早洩治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 早洩治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國早洩治療市場

第19章：中國早洩治療市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Church & Dwight Co., Inc.
  • Menarini Group
Product Code: MRR-030EE48515EB

The Premature Ejaculation Treatment Market was valued at USD 3.52 billion in 2025 and is projected to grow to USD 3.80 billion in 2026, with a CAGR of 8.04%, reaching USD 6.05 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.52 billion
Estimated Year [2026] USD 3.80 billion
Forecast Year [2032] USD 6.05 billion
CAGR (%) 8.04%

Strategic introduction to premature ejaculation treatment landscape, outlining clinical challenges, patient journeys, evolving care paradigms and unmet needs

The treatment of premature ejaculation occupies a complex intersection of clinical science, patient behavior, and commercial innovation. Patients present with heterogeneous symptom profiles and comorbidities that require individualized assessment and therapeutic sequencing. Clinicians balance efficacy, tolerability, onset of action, ease of use, and patient preferences when selecting interventions, which range from behavioral interventions and devices to systemic and topical pharmacotherapies. This landscape is further influenced by evolving regulatory expectations, patient advocacy, and increasing attention to quality of life outcomes.

As stakeholders seek to align product development with clinical need, the role of objective outcome measures and patient-reported outcomes has grown in prominence. Consequently, therapeutic development increasingly emphasizes reproducible effect size on standardized endpoints and meaningful improvements in patient satisfaction. Concurrently, care pathways are adapting to integrate telehealth, remote monitoring, and home-based therapies that support adherence and reduce stigma-related barriers to seeking care. These dynamics create both clinical and commercial opportunities for differentiated therapeutic approaches that deliver demonstrable benefits in real-world settings.

Finally, the interplay between clinician education, payer engagement, and patient awareness determines uptake and sustained use of treatments. Strategic programs that address clinician guidance, optimize patient counseling, and demonstrate comparative advantages of treatment modalities will be critical to translating clinical advances into measurable improvements in care.

Transformations across treatment modalities, digital therapeutics uptake, regulatory shifts and commercial dynamics redefining clinical care and sector focus

Recent years have witnessed substantive shifts that are reshaping how premature ejaculation is conceptualized, diagnosed, and treated. Advances in digital therapeutics and behavioral health delivery have expanded access to evidence-based interventions that were previously constrained to in-person therapy. At the same time, innovations in device design, such as targeted constrictive rings and refined vibratory stimulation platforms, are broadening nonpharmacological options and enabling more patient-centric self-management strategies. These changes are complemented by refinements in topical formulations optimized for rapid onset and predictable tolerability profiles.

Regulatory landscapes are moving toward clearer pathways for combination approaches that pair behavioral interventions with pharmacologic or device-based therapies. This regulatory evolution has encouraged clinical developers to pursue integrated treatment models and to prioritize robust, patient-centered endpoints. In parallel, the commercial environment is responding to greater demand for convenient, discreet, and reimbursable solutions, prompting manufacturers to explore novel distribution channels and support services that improve initiation and adherence.

Taken together, these shifts are creating a more diversified therapeutic ecosystem. Stakeholders that adapt to a multifaceted care framework-one that values convenience, demonstrable patient benefit, and scalable delivery-will be better positioned to meet clinical needs while unlocking new adoption pathways.

Assessment of the 2025 United States tariff environment and its operational, supply chain, and commercial implications for therapeutic and device stakeholders

The introduction of tariffs by the United States in 2025 has introduced a new economic variable for stakeholders involved in the manufacture, importation, and distribution of therapies and devices for premature ejaculation. Supply chains that rely on cross-border sourcing of active pharmaceutical ingredients, device components, or finished goods have experienced increased scrutiny, prompting a reassessment of procurement strategies. Manufacturers and suppliers have responded by evaluating alternative sourcing, regionalizing production, and negotiating supply contracts with greater emphasis on tariff exposure and total landed cost.

This tariff landscape has also affected pricing strategies and launch sequencing, with some organizations electing to localize manufacturing or prioritize strategic inventory to mitigate short-term cost volatility. In addition, contract manufacturers and component suppliers have become more proactive in offering bundled services and value-based arrangements that can offset incremental tariff-related expenses. From a commercial perspective, payers and procurement entities are increasingly focused on cost transparency and predictable pricing models, which can influence formulary decisions and contracting terms.

Importantly, these developments have accelerated conversations around onshoring, strategic supplier partnerships, and long-term supply resilience. As a result, manufacturers that invest in flexible production capacity, dual-sourcing strategies, and proactive tariff modeling will be better equipped to manage cost pressures while preserving access and continuity of care.

In-depth segmentation insights connecting treatment types, end-user channels, and dosage forms to inform product development and commercialization strategies

Segmentation analysis reveals nuanced pathways for product development, commercialization, and clinical adoption, each driven by distinct treatment types, end users, and dosage forms. Based on treatment type, therapeutic approaches encompass nonpharmacological interventions, pharmacological systemic agents, and topical treatments. Nonpharmacological strategies are further differentiated into behavioral therapy and devices, with behavioral therapy subdivided into methods such as sensate focus and start-stop techniques and devices covering modalities like constrictive ring solutions and vibratory stimulation. Pharmacological systemic options include classes such as phosphodiesterase inhibitors and selective serotonin reuptake inhibitors, where the former comprises agents like sildenafil and tadalafil and the latter includes both dedicated agents such as dapoxetine and off-label SSRIs that involve fluoxetine, paroxetine, and sertraline. Topical treatments are characterized by local anesthetics, with common formulations including lidocaine cream, lidocaine-prilocaine spray, and prilocaine cream.

Based on end user, delivery and adoption pathways differ across clinics, home care settings, and hospitals, each presenting unique adoption drivers related to clinician oversight, privacy considerations, and reimbursement. Based on dosage form, patient preference and adherence are influenced by creams, sprays, and tablets, with each form presenting trade-offs in onset, ease of use, and perceived intrusiveness. Taken together, these segmentation dimensions highlight the importance of aligning product design, clinical evidence generation, and patient support programs to the specific needs and behaviors of the intended end users and preferred dosage forms. By mapping clinical benefit profiles to these segment attributes, developers and commercial teams can better prioritize development portfolios and tailor go-to-market strategies that resonate with both prescribers and users.

Key regional dynamics and differentiated strategic approaches required for successful adoption across Americas, Europe Middle East & Africa and Asia-Pacific

Regional dynamics shape regulatory pathways, payer behavior, and clinical practice in distinct ways across the Americas, Europe Middle East & Africa, and Asia-Pacific regions. In the Americas, regulatory frameworks and payer interactions emphasize comparative effectiveness and reimbursement evidence, while health care delivery models favor a mix of clinic-based and home care approaches that accommodate telehealth integration and private payer engagement. In Europe Middle East & Africa, diverse regulatory regimes and heterogeneous health systems necessitate regionally tailored evidence packages and local stakeholder engagement, with certain markets placing heightened emphasis on real-world effectiveness and cost-effectiveness assessments. In the Asia-Pacific region, rapid digital adoption, varying reimbursement landscapes, and a strong focus on localized clinical validation make market entry strategies reliant on partnerships, local regulatory expertise, and culturally adapted patient engagement programs.

Cross-regionally, supply chain considerations, regulatory timelines, and clinician practice patterns influence launch sequencing and resource allocation. The interplay between regional reimbursement policies and patient acceptance of topical versus systemic therapies informs how companies prioritize clinical trials and post-market evidence generation. Therefore, a geographically nuanced approach that aligns evidence generation, regulatory strategy, and commercial operations to regional expectations is essential for achieving sustained adoption and clinical integration.

Company-level strategic trends highlighting product differentiation, partnership models, and evidence generation priorities across the competitive landscape

Competitive activity is increasingly characterized by converging approaches across pharmacologic, device, and behavioral domains, with companies pursuing differentiated formulations, delivery mechanisms, and service-oriented care models. Late-stage developers and established manufacturers are investing in faster-onset topical agents and combination strategies that pair pharmacologic effects with behavioral support, while device innovators focus on usability, discreet form factors, and evidence of durable benefit. Strategic alliances between pharmaceutical developers and digital health providers are also emerging, aiming to bundle therapeutics with adherence and behavioral coaching to enhance outcomes.

In parallel, contract manufacturing and component suppliers are evolving to offer integrated solutions that reduce time to market and mitigate supply chain risks. Clinical development programs increasingly emphasize standardized outcome measures and pragmatic trial designs that capture real-world effectiveness and patient-reported outcomes. Additionally, commercial organizations are refining payer engagement and value demonstration strategies to address reimbursement hurdles, focusing on outcomes that matter to both clinicians and patients.

Collectively, these company-level trends suggest that competitive advantage will accrue to organizations that combine robust clinical evidence, patient-centric delivery models, and supply chain resilience. Firms that can articulate clear value propositions to payers, clinicians, and end users while maintaining flexible operational capabilities will be better positioned to navigate an evolving landscape.

Actionable recommendations for leaders to integrate clinical differentiation, supply chain resilience, and patient-centric commercialization for long-term success

Industry leaders should adopt a multi-pronged strategy that integrates clinical differentiation, supply chain resilience, and patient-centric commercialization. First, prioritizing clinical programs that demonstrate fast onset, favorable tolerability, and meaningful patient-reported outcomes will increase the clinical credibility of new therapies. Second, implementing diversified sourcing strategies and exploring nearshoring or dual-sourcing arrangements can mitigate tariff and supply chain risks while preserving cost competitiveness.

Third, developing integrated care propositions that combine pharmacologic or device therapies with digital behavioral support can enhance adherence and real-world effectiveness. Fourth, engaging early with regulators and payers to define evidence requirements and reimbursement pathways will reduce time to adoption and improve pricing negotiations. Fifth, tailoring market entry and commercialization plans to regional nuances-taking into account regulatory expectations, cultural preferences, and health system structures-will boost local acceptance and uptake. Finally, investing in clinician education and patient support programs that address stigma, set realistic expectations, and simplify use will be essential to drive longer-term adoption.

Collectively, these recommendations encourage organizations to balance innovation with operational rigor and stakeholder alignment, enabling sustainable growth and improved patient outcomes.

Robust mixed-methods research methodology combining primary stakeholder interviews, secondary evidence synthesis and supply chain scenario analysis

The research underpinning this executive summary employed a mixed-methods approach combining primary qualitative interviews, secondary literature synthesis, regulatory document review, and supply chain analysis. Primary research included structured interviews with clinicians, clinical trial investigators, payers, and commercial leaders to capture experiential insights on treatment selection, reimbursement barriers, and patient adherence patterns. Secondary sources encompassed peer-reviewed clinical literature, regulatory guidance documents, clinical trial registries, and patents to validate therapeutic mechanisms, safety signals, and evidence gaps.

Analytical frameworks integrated segmentation mapping, scenario analysis for tariff and supply chain impacts, and comparative assessment of therapeutic modalities across clinical and operational dimensions. Throughout the process, triangulation of data sources ensured that conclusions reflected a balanced synthesis of clinical evidence, stakeholder perspectives, and operational considerations. Limitations of the research-such as evolving regulatory positions and emerging clinical data-were addressed through sensitivity checks and consultation with subject-matter experts. The methodology prioritizes transparency, reproducibility, and alignment with best practices for healthcare market research, thereby providing a defensible basis for the insights and recommendations presented.

Concise conclusion synthesizing clinical, operational, and commercial imperatives to advance care and improve outcomes in premature ejaculation treatment

In summary, the therapeutic landscape for premature ejaculation is in the midst of meaningful evolution, characterized by advances in topical agents, device innovation, digital behavioral supports, and shifting regulatory and commercial dynamics. These trends underscore the importance of an integrated approach that couples robust clinical evidence with patient-centered delivery and resilient operations. Stakeholders that proactively address tariff-induced supply chain vulnerabilities, align product design to end-user preferences across clinics, home care, and hospitals, and demonstrate clear value to payers will be better positioned to capture clinical adoption and sustain commercial performance.

Looking forward, collaborations that bridge pharmacologic, device, and behavioral domains offer the potential to deliver more comprehensive and effective care pathways. Moreover, regionally nuanced strategies that account for differences across the Americas, Europe Middle East & Africa, and Asia-Pacific will be critical to successful implementation. Ultimately, the organizations that combine clinical credibility, operational agility, and stakeholder engagement will lead future advances in care and patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Premature Ejaculation Treatment Market, by Treatment Type

  • 8.1. Non Pharmacological
    • 8.1.1. Behavioral Therapy
      • 8.1.1.1. Sensate Focus
      • 8.1.1.2. Start Stop Technique
    • 8.1.2. Devices
      • 8.1.2.1. Constrictive Ring
      • 8.1.2.2. Vibratory Stimulation
  • 8.2. Pharmacological
    • 8.2.1. Phosphodiesterase Inhibitors
      • 8.2.1.1. Sildenafil
      • 8.2.1.2. Tadalafil
    • 8.2.2. Selective Serotonin Reuptake Inhibitors
      • 8.2.2.1. Dapoxetine
      • 8.2.2.2. Fluoxetine
    • 8.2.3. Local Anesthetics
    • 8.2.4. Combination Pills

9. Premature Ejaculation Treatment Market, by Dosage Form

  • 9.1. Creams
  • 9.2. Sprays
  • 9.3. Tablets

10. Premature Ejaculation Treatment Market, by Route of Administration

  • 10.1. Oral
  • 10.2. Topical

11. Premature Ejaculation Treatment Market, by Onset Type

  • 11.1. Lifelong Premature Ejaculation
  • 11.2. Acquired Premature Ejaculation

12. Premature Ejaculation Treatment Market, by Treatment Accessibility

  • 12.1. Prescription-based
  • 12.2. Over-the-Counter (OTC)

13. Premature Ejaculation Treatment Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals

14. Premature Ejaculation Treatment Market, by Distribution Channel

  • 14.1. Online
  • 14.2. Offline

15. Premature Ejaculation Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Premature Ejaculation Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Premature Ejaculation Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Premature Ejaculation Treatment Market

19. China Premature Ejaculation Treatment Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. Church & Dwight Co., Inc.
  • 20.6. Menarini Group

LIST OF FIGURES

  • FIGURE 1. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PREMATURE EJACULATION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES PREMATURE EJACULATION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA PREMATURE EJACULATION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SENSATE FOCUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SENSATE FOCUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SENSATE FOCUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY START STOP TECHNIQUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY START STOP TECHNIQUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY START STOP TECHNIQUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CONSTRICTIVE RING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CONSTRICTIVE RING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CONSTRICTIVE RING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY VIBRATORY STIMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY VIBRATORY STIMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY VIBRATORY STIMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SILDENAFIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SILDENAFIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SILDENAFIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TADALAFIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TADALAFIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TADALAFIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DAPOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY FLUOXETINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY FLUOXETINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY FLUOXETINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LOCAL ANESTHETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COMBINATION PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COMBINATION PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COMBINATION PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIFELONG PREMATURE EJACULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIFELONG PREMATURE EJACULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY LIFELONG PREMATURE EJACULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ACQUIRED PREMATURE EJACULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ACQUIRED PREMATURE EJACULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ACQUIRED PREMATURE EJACULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PRESCRIPTION-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PRESCRIPTION-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OVER-THE-COUNTER (OTC), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OVER-THE-COUNTER (OTC), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OVER-THE-COUNTER (OTC), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 193. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 207. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL PREMATURE EJACULATION TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 236. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 237. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 238. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 239. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 240. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 242. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 245. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. GCC PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 276. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY NON PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 278. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY BEHAVIORAL THERAPY, 2018-2032 (USD MILLION)
  • TABLE 279. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 280. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHARMACOLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 281. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 284. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY ONSET TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY TREATMENT ACCESSIBILITY, 2018-2032 (USD MILLION)
  • TABLE 287. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. G7 PREMATURE EJACULATION TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

TABLE 289.